These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 25256433)
61. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses. Spencer RJ; Amerena JV Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914 [TBL] [Abstract][Full Text] [Related]
62. Is Apixaban (Eliquis) the "ideal" anticoagulant to replace warfarin for stroke prevention in atrial fibrillation? Strain J; Templeton K S D Med; 2013 Jan; 66(1):20-1. PubMed ID: 23342716 [No Abstract] [Full Text] [Related]
63. Influence of chronic kidney disease on warfarin therapy for atrial fibrillation--reply. Carrero JJ; Szummer K; Jernberg T JAMA; 2014 Jun; 311(24):2542-3. PubMed ID: 25058091 [No Abstract] [Full Text] [Related]
64. Factors in Deciding between Novel and Traditional Oral Anticoagulants to Prevent Embolism in Atrial Fibrillation Patients. Scanavacca M; Darrieux F Arq Bras Cardiol; 2016 Jan; 106(1):1-3. PubMed ID: 26815647 [No Abstract] [Full Text] [Related]
65. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM; Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720 [TBL] [Abstract][Full Text] [Related]
67. Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Roldán V; Marín F; Manzano-Fernandez S; Fernández H; Gallego P; Valdés M; Vicente V; Lip GY Thromb Haemost; 2013 May; 109(5):956-60. PubMed ID: 23572113 [TBL] [Abstract][Full Text] [Related]
68. Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial. van Nieuwenhuizen KM; van der Worp HB; Algra A; Kappelle LJ; Rinkel GJ; van Gelder IC; Schutgens RE; Klijn CJ; Trials; 2015 Sep; 16():393. PubMed ID: 26340977 [TBL] [Abstract][Full Text] [Related]
69. Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Introduction. Palevsky PM Clin J Am Soc Nephrol; 2016 Nov; 11(11):2078. PubMed ID: 27821638 [No Abstract] [Full Text] [Related]
70. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis. Ntaios G; Papavasileiou V; Makaritsis K; Vemmos K; Michel P; Lip GYH Stroke; 2017 Sep; 48(9):2494-2503. PubMed ID: 28716982 [TBL] [Abstract][Full Text] [Related]
71. Chronic kidney disease: one step further in the refinement of risk stratification of atrial fibrillation and impact on the choice of anticoagulant. Providência R; Ferreira MJ; Gonçalves L Thromb Res; 2013 Aug; 132(2):e158-60. PubMed ID: 23910502 [No Abstract] [Full Text] [Related]
72. Clinical characteristics of hemodialysis patients with atrial fibrillation: The RAKUEN (Registry of atrial fibrillation in chronic kidney disease under hemodialysis from Niigata) study. Mitsuma W; Matsubara T; Hatada K; Imai S; Saito N; Shimada H; Miyazaki S J Cardiol; 2016 Aug; 68(2):148-55. PubMed ID: 26527113 [TBL] [Abstract][Full Text] [Related]
73. How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Steinberg BA; Shrader P; Kim S; Thomas L; Fonarow GC; Ansell J; Kowey PR; Singer DE; Gersh BJ; Mahaffey KW; Peterson ED; Piccini JP; Am Heart J; 2016 Nov; 181():145-152. PubMed ID: 27823686 [TBL] [Abstract][Full Text] [Related]
74. Summaries for patients. Rivaroxaban in patients transitioned from vitamin K antagonist therapy. Ann Intern Med; 2013 Jun; 158(12):I-28. PubMed ID: 23778921 [No Abstract] [Full Text] [Related]
75. How to Monitor Patients Receiving Direct Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Practice Tool Endorsed by Thrombosis Canada, the Canadian Stroke Consortium, the Canadian Cardiovascular Pharmacists Network, and the Canadian Cardiovascular Society. Gladstone DJ; Geerts WH; Douketis J; Ivers N; Healey JS; Leblanc K Ann Intern Med; 2015 Sep; 163(5):382-5. PubMed ID: 26121536 [No Abstract] [Full Text] [Related]